Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.

Front Immunol · 2022 · PMC9044076 · PMID 35493455

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a possible trendno p-value reported

Consistent with this hypothesis, a previous analysis of the proportion of patients experiencing a flare over the course of the study and the rate of flares by baseline OCS dosage (0, 0 to ≤5, 5> to ≤10, >10 mg/day), identified a possible trend for increased efficacy of mepolizumab in groups with higher baseline OCS dosage ( 9 ).

also in 1,410 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.